iCare

is a biotechnology and healthcare startup based in Finland that was founded in 2003. The company's slogan, "Establishing the next level of eye care," reflects its mission to provide advanced ophthalmic management solutions. iCare specializes in offering medical devices for screening and diagnosing ocular disease, with a focus on cutting-edge technology, ease of use, and operational reliability. The iCare medical device product line includes retinal imaging, fundus perimeters, rebound tonometers, and software solutions. The retinal imaging technology offers TrueColor Confocal technology, providing enhanced image quality in a fully automated platform and fast, easy diagnostic and retinal screening, including a panoramic option. iCare fundus perimetry is the first automated perimeter combining visual field testing with retinal tracking and fundus imaging, enabling real-time compensation for eye movements and increased test reliability. The rebound tonometry uses patented technology to obtain reliable and rapid IOP measurements without the need for anesthetic drops, making it available for patients to gather more IOP data at home. Additionally, iCare offers intuitive digital tools for software solutions that facilitate efficiency and enhance continuity of care by connecting eye care pathways. As a trusted partner in ophthalmic management, iCare is a registered trademark of Icare Finland Oy, with Icare USA, Inc., Icare World Australia Pty Ltd, and CenterVue S.p.A. all being part of the Revenio Group and representing the brand iCare. Although specific details about the latest investment are not available, iCare aims to establish the next level of eye care by making ophthalmic care accessible, effortless, and reliable.